Paul Tudor Jones's CYTK Position Overview
Paul Tudor Jones (via Tudor Investment Corp Et Al) currently holds 92,680 shares of Cytokinetics, Incorporated (CYTK) worth $7.9 M, representing 0.01% of the portfolio. First purchased in 2014-Q2, this long-term strategic position has been held for 28 quarters.
Based on 13F filings, Paul Tudor Jones has maintained a strategic position in CYTK, demonstrating sustained confidence in this investment. Largest addition occurred in Q3 2025, adding 6 M shares. Largest reduction occurred in Q4 2025, reducing 6 M shares.
Analysis based on 13F filings available since 2013 Q2
Paul Tudor Jones's Cytokinetics Incorporated (CYTK) Holding Value Over Time
Track share changes against reported price movement
Quarterly Cytokinetics Incorporated (CYTK) Trades by Paul Tudor Jones
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q2 2026 | +92,680 | New Buy | 92,680 | $85.19 |
| Q4 2025 | -6 M | Sold Out | 0 | $0.00 |
| Q3 2025 | +6 M | New Buy | 6 M | $1.14 |
| Q3 2024 | -74,989 | Sold Out | 0 | $0.00 |
| Q2 2024 | -747 | Reduce 0.99% | 74,989 | $54.18 |
| Q1 2024 | +40,009 | Add 111.99% | 75,736 | $70.11 |
| Q4 2023 | +35,727 | New Buy | 35,727 | $83.49 |
| Q2 2023 | -32,241 | Sold Out | 0 | $0.00 |
| Q1 2023 | +13,878 | Add 75.58% | 32,241 | $0.04 |
| Q4 2022 | -45,495 | Reduce 71.24% | 18,363 | $0.05 |
| Q3 2022 | +33,154 | Add 107.98% | 63,858 | $48.45 |
| Q2 2022 | +30,704 | New Buy | 30,704 | $39.28 |
| Q3 2021 | -24,317 | Sold Out | 0 | $0.00 |
| Q2 2021 | -21,475 | Reduce 46.90% | 24,317 | $19.78 |
| Q1 2021 | +45,792 | New Buy | 45,792 | $23.26 |
| Q2 2017 | -26,166 | Sold Out | 0 | $0.00 |
| Q1 2017 | +8,926 | Add 51.77% | 26,166 | $12.84 |
| Q4 2016 | -24,060 | Reduce 58.26% | 17,240 | $12.12 |
| Q3 2016 | +24,830 | Add 150.76% | 41,300 | $9.18 |
| Q2 2016 | +1,462 | Add 9.74% | 16,470 | $9.47 |
| Q1 2016 | -12,664 | Reduce 45.76% | 15,008 | $7.06 |
| Q4 2015 | +8,080 | Add 41.24% | 27,672 | $10.44 |
| Q3 2015 | +2,501 | Add 14.63% | 19,592 | $6.69 |
| Q2 2015 | -7,402 | Reduce 30.22% | 17,091 | $6.73 |
| Q1 2015 | +11,615 | Add 90.19% | 24,493 | $6.78 |
| Q4 2014 | -1,350 | Reduce 9.49% | 12,878 | $8.00 |
| Q3 2014 | -24,741 | Reduce 63.49% | 14,228 | $3.51 |
| Q2 2014 | +38,969 | New Buy | 38,969 | $4.77 |
Paul Tudor Jones's Cytokinetics Incorporated Investment FAQs
Paul Tudor Jones first purchased Cytokinetics, Incorporated (CYTK) in Q2 2014, acquiring 38,969 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Paul Tudor Jones has held Cytokinetics, Incorporated (CYTK) for 28 quarters since Q2 2014.
Paul Tudor Jones's largest addition to Cytokinetics, Incorporated (CYTK) was in Q3 2025, adding 6,000,000 shares worth $6.86 M.
According to the latest 13F filing for Q2 2026, Paul Tudor Jones's firm, Tudor Investment Corp Et Al, owns 92,680 shares of Cytokinetics, Incorporated (CYTK), valued at approximately $7.9 M.
As of the Q2 2026 filing, Cytokinetics, Incorporated (CYTK) represents approximately 0.01% of Paul Tudor Jones's publicly disclosed stock portfolio, making it one of their key holdings.
Paul Tudor Jones's peak holding in Cytokinetics, Incorporated (CYTK) was 6,000,000 shares, as reported at the end of Q3 2025.